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Effect of dietary β-sitosterol on fecal bacterial and colonic
biotransformation enzymes in 1,2-dimethylhydrazine–induced
colon carcinogenesis
Albert Baskar ARUL1, Khalid AL NUMAIR1, Mohammed AL SAIF1, Ignacimuthu SAVARIMUTHU2

Aim: The present study was designed to investigate the modulatory effect of β-sitosterol administration on
1,2-dimethylhydrazine (DMH)-induced fecal bacterial and colonic biotransformation enzyme activities.
Materials and methods: The chemopreventive potential of β-sitosterol in colon carcinogenesis was assessed by injecting
DMH (20 mg/kg body weight) subcutaneously into male Wistar rats and supplementing with β-sitosterol throughout
the experimental period of 16 weeks at 3 different doses (5, 10, and 20 mg/kg body weight).
Results: Amplified activities of fecal bacterial (β-glucuronidase, β-glucosidase, β-galactosidase, nitroreductase,
hyaluronate lyase, and sulfatase) and colonic biotransformation (β-glucuronidase, β-glucosidase, β-galactosidase, and
nitroreductase) enzymes were considered hallmarks of colon carcinogenesis. DMH-induced animals showed increased
activities of fecal bacterial and colonic biotransformation enzymes. Treatment with β-sitosterol markedly decreased the
fecal bacterial and colonic biotransformation enzymes and reverted the colonic tissue to near normal.
Conclusion: The results of the present study revealed that β-sitosterol markedly inhibited DMH-induced colon
carcinogenesis by its ability to ameliorate the fecal bacterial and colonic biotransformation enzymes. Hence, β-sitosterol
can be a potential chemopreventive agent towards colon carcinogenesis.
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Introduction
Lung, breast, and colon cancer are the 3 most
common cancers worldwide, with an increasing
annual incidence (1). Considerable interest has
been focused on the metabolic activities of the
intestinal microflora, especially in relation to the
etiology of colon cancer. The intestinal bacteria play
a crucial role in the development of carcinogenesis
(2–5). Experimentally induced colon tumors
involve activation of the procarcinogen to an active
carcinogen mediated by bacterial enzymes. The
carcinogens are excreted into the bile as glucuronides
and are activated by glucuronidase in the intestinal

track by enzymatic hydrolysis. Inhibition of this
glucuronidase reduced the incidence of colon cancer
in rats (6–9).
1,2-Dimethylhydrazine (DMH)-induced colon
carcinogenesis in male Wistar rats is a widely used
experimental model among cancer chemoprevention
studies. During the process of experimental colon
carcinogenesis, dysplastic crypts appear in the early
stage and eventually develop into tumors (10). The
goal of cancer chemoprevention is to retard, block,
or reverse the process of carcinogenesis through
the use of natural or synthetic agents, including
antioxidants. Asclepias curassavica powder is used
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to treat abdominal tumors in the traditional system
of Indian medicine. β-Sitosterol and its glycosides,
along with other compounds such as oleanolic acid,
uzarigenin, calactin, calotropin, coroglaucigenin,
calotropagenin, and uzarin have been isolated from
A. curassavica (11).
β-Sitosterol, isolated from various plants,
promotes apoptosis by increasing Fas levels
and caspase-8 activity (12), phosphorylation of
extracellular-signal regulating kinase (ERK), and p38
mitogen-activated protein kinase (MAPK) (13). Even
at low concentrations with no cytotoxic effect on
noncancerous cells (14), β-sitosterol works to inhibit
cancer cell proliferation by modulating antioxidant
enzyme levels in pathogenesis (15), arresting prostate
cancer cells at the G2/M phase (16), and decreasing
free radical generation in vitro (17). β-Sitosterol
shows great cancer chemopreventive potential in
DMH-induced animals (18). A large number of
medicinal plants and their purified constituents have
beneficial therapeutic potentials. In this context,
our work aimed to broaden the understanding of
the anticancer potential of β-sitosterol in a DMHinduced experimental colon carcinogenesis model,
which could be beneficial in anticancer therapy.
Materials and methods
Chemicals
In this study, extraction, separation, and purification
of β-sitosterol were done as reported by us previously
(18) from A. curassavica. DMH, p-nitrophenylβ-D-glucopyranoside,
p-nitrophenyl-β-Dglucoside,
p-nitrophenyl-β-D-galactopyranoside,
p-nitrocatechol sulfate, and p-nitrobenzoic acid
were purchased from Sigma Chemical Company,
Bangalore, India. All other chemicals, including
solvents, were of high purity and analytical grade,
marketed by HiMedia Chemicals, Mumbai, India.

Law on Animal Care and Use (Reg. No. 833/a/2
004/CPC SEA). The animals were housed 4 per
cage in polypropylene cages with a wire mesh top
and a hygienic bed of husk in a specific pathogenfree animal room under controlled conditions of
12 h light/12 h dark, with temperatures of 24 ± 2
°C and relative humidity of 50 ± 10% until the end
of the experimental period. The rats were held in
quarantine for 1 week and had access to food and tap
water ad libitum. A commercial pellet diet containing
4.2% fat (Hindustan Lever Ltd, Mumbai, India) was
powdered and mixed with 15.8% peanut oil, making
a total of 20% fat in the diet. This modified powdered
pellet diet was fed to the rats in all groups throughout
the experimental period of 16 weeks.
Experimental design
The experimental animals were divided into 6 groups
with 10 animals in each group. The initial body weights
of all animals in this study protocol were measured to
be between 80 and 120 g. The animals’ weights were
recorded once a week throughout the experimental
period and prior to sacrifice. The animals in groups
3–6 received subcutaneous injections of DMH at a
dose of 20 mg/kg body weight once a week for the
first 4 consecutive weeks. Prior to subcutaneous
injection, DMH was dissolved in 1 mL of EDTA. The
pH was adjusted to 6.5 with 1 mL of NaOH to ensure
the pH and stability of the chemical, and it was used
immediately after preparation.
Treatment of β-sitosterol for the animals
Group 1: Rats received a modified pellet diet along
with intragastric intubation of 0.1%
carboxymethyl cellulose (CMC; 1.0 mL)
throughout the experimental period.

Animals

Group 2: Rats received a modified pellet diet + 20
mg/kg body weight β-sitosterol suspended
in 0.1% CMC (1.0 mL), peroral (p.o.),
every day throughout the experimental
period.

Experiments were carried out with male Wistar rats
aged 5 weeks, obtained from the Central Animal
House, King Institute, Chennai, Tamil Nadu, India.
The animals were cared for in compliance with the
principles and guidelines of the Ethical Committee
for Animal Care and the Institutional Animal Ethical
Committee, in accordance with the Indian National

Group 4: Rats were treated as in group 3 along with
β-sitosterol (5 mg/kg body weight, p.o.)
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Group 3: Rats were administered with 20 mg/kg
body weight DMH subcutaneously once
a week for 4 consecutive weeks and kept
without any treatment for the next 12
weeks.

A. B. ARUL, K. AL NUMAIR, M. AL SAIF, I. SAVARIMUTHU

supplemented daily throughout the entire
experimental period of 16 weeks.
Group 5: Rats were treated as in group 3 along with
β-sitosterol (10 mg/kg body weight, p.o.)
supplemented daily throughout the entire
experimental period of 16 weeks.
Group 6: Rats were treated as in group 3 along with
β-sitosterol (20 mg/kg body weight, p.o.)
supplemented daily throughout the entire
experimental period of 16 weeks.
At the end of 16 weeks, all of the animals
were sacrificed under anesthesia (intraperitoneal
administration of ketamine hydrochloride (30 mg/
kg body weight) by cervical dislocation between
0800 and 1000 hours after an overnight fast. Tissue
samples were immediately transferred to ice-cold
containers, weighed, and homogenized using an
appropriate buffer in a tissue homogenizer. At the end
of the experimental period, fresh fecal pellets were
collected and the activity of hyaluronate lyase was
estimated using the method of Shiau and Chang (19).
The normal mucosa was compared with the abnormal
mucosa. The rest of the tissues and the colon contents
of 10 rats of each group were transferred to ice-cold
containers to measure the activity of β-glucuronidase,
β-glucosidase, and β-galactosidase using the method
of Freeman (20). The activity of nitroreductase was

estimated using the method of Bratton and Marshall
(21). Sulfatase was measured using the method of
Rowland et al. (22). Proteins were estimated using
the method of Lowry et al. (23).
Statistical analysis
The statistical significance of the data was determined
using one-way analysis of variance, and significant
differences among treatment groups were evaluated
by Duncan’s multiple range test. The results were
considered statistically significant at P < 0.05. All
statistical analyses were made using SPSS 11.0 (SPSS,
Tokyo, Japan).
Results
Effect of β-sitosterol on fecal (bacterial) enzymes
Table
1
summarizes
the
β-glucuronidase, β-glucosidase,

activities
of
β-galactosidase,

and nitroreductase in fresh fecal samples. The
activities of these enzymes were increased 2–3
times in rats treated with DMH alone (group 3) as
compared to the rats in the control group (group
1). The activities were reduced in all β-sitosterol–
supplemented rats (groups 4–6) as compared to rats
treated with DMH alone (group 3). Furthermore,
there was a significantly (P < 0.01) greater reduction
in β-glucuronidase, β-glucosidase, β-galactosidase,

Table 1. Effect of β-sitosterol supplementation on fecal bacterial β-glucuronidase, β-glucosidase, and β-galactosidase
enzyme activities in control and experimental rats.

Groups

β-Glucuronidase

β-Glucosidase

β-Galactosidase

mg of p-nitrophenol liberated/min/g protein

Control

19 ± 1a

48 ± 3a

28 ± 2a

Control + β-sitosterol (20 mg/kg)

20 ± 1ab

50 ± 3a

29 ± 2a

DMH

27 ± 2c

108 ± 8b

71 ± 5b

DMH + β-sitosterol (5 mg/kg)

25 ± 1cd

103 ± 7bc

68 ± 5bc

DMH + β-sitosterol (10 mg/kg)

24 ± 1d

100 ± 7c

65 ± 5c

DMH + β-sitosterol (20 mg/kg)

21 ± 1b*

70 ± 5d*

44 ± 3d*

Data are presented as means ± SD of 10 rats in each group. a-d: values not sharing a common superscript letter are
significantly different at P < 0.05. *: values are significantly different at P < 0.01 as compared to the group treated with
DMH alone.
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hyaluronate lyase, and nitroreductase (21%, 45%,
37%, 41%, and 26%, respectively) activities in
animals supplemented with high dose of β-sitosterol
for the entire period (group 6) as compared to the
other β-sitosterol–supplemented groups.
Table 2 shows the fecal nitroreductase, hyaluronate
lyase, and sulfatase activity following β-sitosterol
supplementation in the different treatment regimens.
In carcinogen-treated rats (group 3), mean activities
of the enzymes were elevated 2-fold compared to rats
in the control group (group 1). In addition, there was
a significant (P < 0.05) reduction in the fecal enzyme
activity in animals supplemented with medium

dose of β-sitosterol; the animals supplemented
with β-sitosterol at a high dose (group 6) showed
significantly (P < 0.01) greater reduction in the
enzyme activity.
Effect of β-sitosterol on colonic (mucosal)
biotransforming enzyme activities
Table
3
represents
the
activities
of
colonic
mucosal
enzymes.
After
the 16 weeks of the experimental period,
the
colonic
mucosal
enzymes,
such
as β-glucuronidase, β-glucosidase, β-galactosidase,
and nitroreductase, had activity that was 2–3 times

Table 2. Effect of β-sitosterol supplementation on fecal bacterial hyaluronate lyase, sulfatase, and nitroreductase activities in control
and experimental rats.
Groups

Hyaluronate lyase ‡

Sulfatase#

Nitroreductase@

Control

2.7 ± 0.2a

26 ± 2a

21 ± 1a

Control + β-sitosterol (20 mg/kg)

2.8 ± 0.2a

26 ± 2a

21 ± 1a

DMH

5.5 ± 0.5b

61 ± 4b

36 ± 2b

DMH + β-sitosterol (5 mg/kg)

5.2 ± 0.3bc

58 ± 4bc

34 ± 2bc

DMH + β-sitosterol (10 mg/kg)

5.1 ± 0.3c

51 ± 3c

33 ± 2c

DMH + β-sitosterol (20 mg/kg)

3.3 ± 0.2d*

34 ± 2d*

27 ± 2d*

: mg of glucose liberated/min/mg protein, #: µmol of p-nitrocatechol liberated/min/g protein, @: µmol of p-aminobenzoic liberated/
min/g protein.
Data are presented as means ± SD of 10 rats in each group. a-d: values not sharing a common superscript letter are significantly different
at P < 0.05. *: values are significantly different at P < 0.01 as compared to the group treated with DMH alone.

‡

Table 3. Effect of β-sitosterol supplementation on colonic biotransformation enzymes of control and experimental rats.
b-Glucuronidase
Groups

b-Glucosidase

b-Galactosidase

Nitroreductase

µg of p-nitrophenol liberated/h/g protein

µmol of p-aminobenzoic
liberated/min/g protein

Control

8 ± 0.6a

25 ± 1a

22 ± 1a

12 ± 0.9a

Control + β-sitosterol (20 mg/kg)

9 ± 0.6a

26 ± 2a

23 ± 1a

13 ± 1a

DMH

16 ± 1.2b

67 ± 5b

44 ± 3b

24 ± 1b

DMH + β-sitosterol (5 mg/kg)

15 ± 1.1bc

65 ± 4bc

41 ± 3bc

23 ± 1bc

DMH + β-sitosterol (10 mg/kg)

11 ± 0.8c

62 ± 4c

42 ± 3c

22 ± 1c

DMH + β-sitosterol (20 mg/kg)

12 ± 0.9d*

40 ± 3d*

28 ± 2d*

15 ± 1d*

Data are presented as means ± SD of 10 rats in each group. a-d: values not sharing a common superscript letter are significantly different
at P < 0.05. *: values are significantly different P < 0.01 as compared to group treated with DMH alone.
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higher (P < 0.05) in rats treated with DMH alone
(group 3) than in the control rats (group 1), whereas
the activities of these enzymes were significantly
(P < 0.05) reduced in DMH-administered rats
supplemented with β-sitosterol (groups 5 and 6) when
compared to the unsupplemented DMH-treated rats
(group 3). Significantly (P < 0.01) greater reduction
in the percentage of β-glucuronidase, β-glucosidase,
β-galactosidase, and nitroreductase activities (35%,
42%, 36%, and 39%, respectively) was observed in
rats supplemented with a high dose of β-sitosterol
during the entire period (group 6) of the study.
Discussion
In rats exposed to DMH alone, the body weight gain
and growth rate were reduced compared to the control
throughout the experimental period. The reduction
in body weight gain and growth rate observed in
rats treated with DMH alone may be an integral
part of the carcinogenic process. Cachexia (catabolic
clinical state) may be caused by a combination of
endocrine and immunological disturbances resulting
from host–tumor interactions. The body weight gain
and growth rate were significantly improved in rats
with β-sitosterol supplementation. Although the
mechanisms of body weight gain during β-sitosterol
supplementation are unknown, the relationship
appears to be complex, since body weight gain and
growth rate are thought to be regulated by a variety
of interactions involving food intake, carcinogenicity,
and the consequent tumor burden.
A number of studies have suggested a key
role played by certain resident gut bacteria in the
development of large bowel cancer. Epidemiological
studies and laboratory research have indicated a
strong association between the metabolic activity
of the intestinal microflora and cancer of the large
bowel (24). The activation of procarcinogens could
be mediated enzymatically by intestinal bacteria,
and the activities of colonic bacterial enzymes
are increased by dietary fat (25,26). On DMH
administration we observed increased colonic and
fecal activities of carcinogen-retoxifying enzymes
such as β-glucuronidase, β-glucosidase, and
β-galactosidase. Increased expression of intestinal
mucosal β-glucuronidase, β-glucosidase, and
β-galactosidase in relation to a high risk of colon

cancer is well documented (24). In addition, it
has been reported that E. coli, a β-glucuronidase–
positive bacteria, increases the production of active
carcinogenic metabolites in the colon and is thus
responsible for colon carcinogenesis (27).
Epithelial mucins are a family of secretory
cell surface glycoproteins expressed by epithelial
tissues. Many human mucin genes appear to encode
mucin to protect and lubricate epithelial tissues by
forming a viscoelastic gel layer (28). Hyaluronate
lyase, a hydrolytic enzyme secreted by the intestinal
microflora, degrades the protective mucous layer of
the colon (24). A change in hyaluronate lyase activity
is accompanied by a change in the rate of mucin
degradation, leading to a shift in the balance between
mucin secretion and degradation (29). Enhanced
degradation of the mucosal lining of colonic
epithelial cells (mucin) ensures a greater contact of
the toxic carcinogen with the colonocytes. This may
be accompanied by an increased susceptibility of the
colonic cells to being transformed (20).
Measurements of colonic bacterial and fecal
biotransforming enzyme activities in rats exposed to
DMH were found to be several times higher when
compared to the control rats. The influence of diet
on tumor development and its relationship to DMHretoxifying enzymes have been used extensively to test
the influence of diet on colon carcinogenesis (30). The
activities of these bacterial enzymes were significantly
decreased following β-sitosterol supplementation,
especially when 20 mg/kg body weight DMH was
supplemented throughout the study period (group
6). Reduction of bacterial enzyme activity in the large
bowel is paralleled by a decrease in the frequency of
colonic aberrant crypt foci (27).
We
previously
reported
the
cancer
chemopreventive potential of β-sitosterol in DMHinduced experimental colon carcinogenesis by virtue
of its radical quenching ability with minimal toxic
effects to the normal cells (VERO: monkey kidney
cell line). The antioxidant potential of β-sitosterol
may be responsible for the chemopreventive potential
of DMH-induced experimental carcinogenesis (18).
In our present study, β-sitosterol supplementation to
DMH-induced animals decreased the levels of the fecal
bacterial and colonic biotransformation enzymes in a
dose-dependent manner. The antibacterial activity of
1311
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β-sitosterol may be responsible for the reduction in
the enzyme levels by controlling the gut microflora
to near-normal activity.
The present study demonstrates that β-sitosterol
offers protection to the colon from DMHinduced experimental colon carcinogenesis by
restoring the activities of fecal bacterial and
colonic biotransformation enzymes in a dosedependent manner. Hence, β-sitosterol can be a
potential chemopreventive agent against colon
carcinogenesis.
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